Engineered immune cells take aim at Hard-to-Treat myeloma
NCT ID NCT03710421
First seen Apr 16, 2026 · Last updated Jun 11, 2026 · Updated 9 times
Summary
This early-phase study tests a new treatment for multiple myeloma that has come back or stopped responding to standard therapy. The treatment uses the patient's own immune cells, which are modified in a lab to recognize and attack myeloma cells. About 30 adults will receive these engineered cells after a short course of chemotherapy to prepare their body. The main goals are to find the safest dose and understand side effects.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for RECURRENT PLASMA CELL MYELOMA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
City of Hope Medical Center
RECRUITINGDuarte, California, 91010, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
Conditions
Explore the condition pages connected to this study.